IM Cannabis Achieves Positive Operating Cash Flow and 134% German Revenue Growth in 2025 Results
IMCC sits 70% above its 52-week low of $0.304.
Summary
IM Cannabis Corp. reported strong 2025 financial results, achieving positive operating cash flow of C$4.7 million and over 134% revenue growth in Germany, while also strengthening its cash position.
Key Events · Earnings and Guidance · IMCC
-
Achieved Positive Operating Cash Flow
The company reported positive cash flow from operating activities of C$4.7 million for the full year 2025, a significant turnaround from negative cash flow in 2024 and its first full year of positive operating cash flow in recent history.
-
Strong German Revenue Growth
Germany revenue surged over 134% to C$36.348 million, now representing more than 66% of total Group revenue, underscoring successful market penetration and EU-GMP-certified production.
-
Stable Overall Revenue
Total revenue reached C$54.731 million, demonstrating resilience and stability despite ongoing challenges in the Israeli market.
-
Strengthened Cash Position
Cash and restricted cash rose sharply to C$3.309 million at year-end 2025, up from C$0.927 million at year-end 2024, bolstered by strategic financings.
Analysis · IMCC · Life Sciences
This filing reports IM Cannabis Corp.'s 2025 financial results, highlighting a significant operational turnaround. The company achieved positive operating cash flow for the first time in recent history, a critical milestone for a small-cap company, indicating improved financial health and sustainability. The substantial revenue growth in Germany, now accounting for over two-thirds of total revenue, demonstrates successful market penetration and strategic diversification away from challenges in Israel. The strengthened cash position through recent financing further supports its operational runway. These results provide a strong positive signal regarding the company's execution of its strategic initiatives and its ability to generate cash.
At the time of this filing, IMCC was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.30 to $7.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.